nodes	percent_of_prediction	percent_of_DWPC	metapath
Tizanidine—NISCH—Podofilox—Teniposide—lymphatic system cancer	0.0202	0.709	CbGdCrCtD
Tizanidine—NISCH—Vinblastine—Vincristine—lymphatic system cancer	0.00826	0.29	CbGdCrCtD
Tizanidine—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00162	0.00167	CcSEcCtD
Tizanidine—Dyspepsia—Fludarabine—lymphatic system cancer	0.00161	0.00166	CcSEcCtD
Tizanidine—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00161	0.00165	CcSEcCtD
Tizanidine—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.0016	0.00164	CcSEcCtD
Tizanidine—Fatigue—Fludarabine—lymphatic system cancer	0.00158	0.00163	CcSEcCtD
Tizanidine—Hallucination—Vincristine—lymphatic system cancer	0.00157	0.00162	CcSEcCtD
Tizanidine—Constipation—Fludarabine—lymphatic system cancer	0.00157	0.00161	CcSEcCtD
Tizanidine—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00156	0.00161	CcSEcCtD
Tizanidine—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00156	0.0016	CcSEcCtD
Tizanidine—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00155	0.0016	CcSEcCtD
Tizanidine—Urethral disorder—Vincristine—lymphatic system cancer	0.00155	0.00159	CcSEcCtD
Tizanidine—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00154	0.00159	CcSEcCtD
Tizanidine—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00154	0.00158	CcSEcCtD
Tizanidine—Hypersensitivity—Teniposide—lymphatic system cancer	0.00154	0.00158	CcSEcCtD
Tizanidine—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00154	0.00158	CcSEcCtD
Tizanidine—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00154	0.00158	CcSEcCtD
Tizanidine—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00153	0.00157	CcSEcCtD
Tizanidine—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00152	0.00157	CcSEcCtD
Tizanidine—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.00152	0.00157	CcSEcCtD
Tizanidine—Pulmonary embolism—Methotrexate—lymphatic system cancer	0.00152	0.00157	CcSEcCtD
Tizanidine—Anaemia—Bleomycin—lymphatic system cancer	0.00152	0.00157	CcSEcCtD
Tizanidine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00151	0.00156	CcSEcCtD
Tizanidine—Asthenia—Teniposide—lymphatic system cancer	0.0015	0.00154	CcSEcCtD
Tizanidine—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.00149	0.00153	CcSEcCtD
Tizanidine—Melaena—Methotrexate—lymphatic system cancer	0.00149	0.00153	CcSEcCtD
Tizanidine—Malaise—Bleomycin—lymphatic system cancer	0.00149	0.00153	CcSEcCtD
Tizanidine—Pruritus—Teniposide—lymphatic system cancer	0.00148	0.00152	CcSEcCtD
Tizanidine—Arrhythmia—Carmustine—lymphatic system cancer	0.00148	0.00152	CcSEcCtD
Tizanidine—Leukopenia—Bleomycin—lymphatic system cancer	0.00147	0.00152	CcSEcCtD
Tizanidine—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.00147	0.00151	CcSEcCtD
Tizanidine—Cystitis—Methotrexate—lymphatic system cancer	0.00147	0.00151	CcSEcCtD
Tizanidine—Cardiac disorder—Vincristine—lymphatic system cancer	0.00146	0.00151	CcSEcCtD
Tizanidine—Alopecia—Carmustine—lymphatic system cancer	0.00146	0.0015	CcSEcCtD
Tizanidine—Body temperature increased—Fludarabine—lymphatic system cancer	0.00145	0.00149	CcSEcCtD
Tizanidine—Mental disorder—Carmustine—lymphatic system cancer	0.00145	0.00149	CcSEcCtD
Tizanidine—Vaginal infection—Methotrexate—lymphatic system cancer	0.00144	0.00148	CcSEcCtD
Tizanidine—Angiopathy—Vincristine—lymphatic system cancer	0.00143	0.00147	CcSEcCtD
Tizanidine—Diarrhoea—Teniposide—lymphatic system cancer	0.00143	0.00147	CcSEcCtD
Tizanidine—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00142	0.00146	CcSEcCtD
Tizanidine—Alopecia—Vincristine—lymphatic system cancer	0.00139	0.00143	CcSEcCtD
Tizanidine—Back pain—Carmustine—lymphatic system cancer	0.00139	0.00143	CcSEcCtD
Tizanidine—Discomfort—Bleomycin—lymphatic system cancer	0.00139	0.00143	CcSEcCtD
Tizanidine—Mental disorder—Vincristine—lymphatic system cancer	0.00138	0.00142	CcSEcCtD
Tizanidine—Ecchymosis—Methotrexate—lymphatic system cancer	0.00138	0.00142	CcSEcCtD
Tizanidine—Bladder pain—Methotrexate—lymphatic system cancer	0.00138	0.00142	CcSEcCtD
Tizanidine—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00137	0.00141	CcSEcCtD
Tizanidine—Alopecia—Mitoxantrone—lymphatic system cancer	0.00136	0.0014	CcSEcCtD
Tizanidine—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.00136	0.0014	CcSEcCtD
Tizanidine—Confusional state—Bleomycin—lymphatic system cancer	0.00136	0.0014	CcSEcCtD
Tizanidine—Vision blurred—Carmustine—lymphatic system cancer	0.00136	0.00139	CcSEcCtD
Tizanidine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00135	0.00139	CcSEcCtD
Tizanidine—Tremor—Carmustine—lymphatic system cancer	0.00135	0.00139	CcSEcCtD
Tizanidine—Oedema—Bleomycin—lymphatic system cancer	0.00134	0.00138	CcSEcCtD
Tizanidine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00134	0.00138	CcSEcCtD
Tizanidine—Infection—Bleomycin—lymphatic system cancer	0.00134	0.00137	CcSEcCtD
Tizanidine—Anaemia—Carmustine—lymphatic system cancer	0.00133	0.00137	CcSEcCtD
Tizanidine—Back pain—Vincristine—lymphatic system cancer	0.00133	0.00137	CcSEcCtD
Tizanidine—Vomiting—Teniposide—lymphatic system cancer	0.00133	0.00137	CcSEcCtD
Tizanidine—Sepsis—Methotrexate—lymphatic system cancer	0.00132	0.00136	CcSEcCtD
Tizanidine—Agitation—Carmustine—lymphatic system cancer	0.00132	0.00136	CcSEcCtD
Tizanidine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00132	0.00136	CcSEcCtD
Tizanidine—Asthenia—Fludarabine—lymphatic system cancer	0.00132	0.00135	CcSEcCtD
Tizanidine—Rash—Teniposide—lymphatic system cancer	0.00132	0.00135	CcSEcCtD
Tizanidine—Dermatitis—Teniposide—lymphatic system cancer	0.00131	0.00135	CcSEcCtD
Tizanidine—Pruritus—Fludarabine—lymphatic system cancer	0.0013	0.00134	CcSEcCtD
Tizanidine—Back pain—Mitoxantrone—lymphatic system cancer	0.00129	0.00133	CcSEcCtD
Tizanidine—Leukopenia—Carmustine—lymphatic system cancer	0.00129	0.00132	CcSEcCtD
Tizanidine—Anaemia—Vincristine—lymphatic system cancer	0.00127	0.00131	CcSEcCtD
Tizanidine—Agitation—Vincristine—lymphatic system cancer	0.00126	0.0013	CcSEcCtD
Tizanidine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00126	0.0013	CcSEcCtD
Tizanidine—Hypotension—Bleomycin—lymphatic system cancer	0.00126	0.00129	CcSEcCtD
Tizanidine—Diarrhoea—Fludarabine—lymphatic system cancer	0.00125	0.00129	CcSEcCtD
Tizanidine—Convulsion—Carmustine—lymphatic system cancer	0.00125	0.00128	CcSEcCtD
Tizanidine—Hypertension—Carmustine—lymphatic system cancer	0.00124	0.00128	CcSEcCtD
Tizanidine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00124	0.00128	CcSEcCtD
Tizanidine—Nausea—Teniposide—lymphatic system cancer	0.00124	0.00128	CcSEcCtD
Tizanidine—Anaemia—Mitoxantrone—lymphatic system cancer	0.00124	0.00127	CcSEcCtD
Tizanidine—Vertigo—Vincristine—lymphatic system cancer	0.00123	0.00127	CcSEcCtD
Tizanidine—Hepatic failure—Methotrexate—lymphatic system cancer	0.00123	0.00127	CcSEcCtD
Tizanidine—Leukopenia—Vincristine—lymphatic system cancer	0.00123	0.00126	CcSEcCtD
Tizanidine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00123	0.00126	CcSEcCtD
Tizanidine—Anxiety—Carmustine—lymphatic system cancer	0.00122	0.00126	CcSEcCtD
Tizanidine—Paraesthesia—Bleomycin—lymphatic system cancer	0.00121	0.00124	CcSEcCtD
Tizanidine—Malaise—Mitoxantrone—lymphatic system cancer	0.00121	0.00124	CcSEcCtD
Tizanidine—Dyspnoea—Bleomycin—lymphatic system cancer	0.0012	0.00123	CcSEcCtD
Tizanidine—Renal failure acute—Methotrexate—lymphatic system cancer	0.0012	0.00123	CcSEcCtD
Tizanidine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.0012	0.00123	CcSEcCtD
Tizanidine—Convulsion—Vincristine—lymphatic system cancer	0.00119	0.00122	CcSEcCtD
Tizanidine—Hypertension—Vincristine—lymphatic system cancer	0.00119	0.00122	CcSEcCtD
Tizanidine—Confusional state—Carmustine—lymphatic system cancer	0.00118	0.00122	CcSEcCtD
Tizanidine—Oedema—Carmustine—lymphatic system cancer	0.00117	0.00121	CcSEcCtD
Tizanidine—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00117	0.00121	CcSEcCtD
Tizanidine—Infection—Carmustine—lymphatic system cancer	0.00117	0.0012	CcSEcCtD
Tizanidine—Vomiting—Fludarabine—lymphatic system cancer	0.00117	0.0012	CcSEcCtD
Tizanidine—Convulsion—Mitoxantrone—lymphatic system cancer	0.00116	0.00119	CcSEcCtD
Tizanidine—Rash—Fludarabine—lymphatic system cancer	0.00116	0.00119	CcSEcCtD
Tizanidine—Dermatitis—Fludarabine—lymphatic system cancer	0.00116	0.00119	CcSEcCtD
Tizanidine—Hypertension—Mitoxantrone—lymphatic system cancer	0.00115	0.00119	CcSEcCtD
Tizanidine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00115	0.00118	CcSEcCtD
Tizanidine—Tachycardia—Carmustine—lymphatic system cancer	0.00115	0.00118	CcSEcCtD
Tizanidine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00114	0.00117	CcSEcCtD
Tizanidine—Anxiety—Mitoxantrone—lymphatic system cancer	0.00113	0.00117	CcSEcCtD
Tizanidine—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.00113	0.00116	CcSEcCtD
Tizanidine—Discomfort—Mitoxantrone—lymphatic system cancer	0.00112	0.00116	CcSEcCtD
Tizanidine—Oedema—Vincristine—lymphatic system cancer	0.00112	0.00115	CcSEcCtD
Tizanidine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00112	0.00115	CcSEcCtD
Tizanidine—Infection—Vincristine—lymphatic system cancer	0.00111	0.00115	CcSEcCtD
Tizanidine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00111	0.00114	CcSEcCtD
Tizanidine—Confusional state—Mitoxantrone—lymphatic system cancer	0.0011	0.00113	CcSEcCtD
Tizanidine—Nervous system disorder—Vincristine—lymphatic system cancer	0.0011	0.00113	CcSEcCtD
Tizanidine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.0011	0.00113	CcSEcCtD
Tizanidine—Hypotension—Carmustine—lymphatic system cancer	0.0011	0.00113	CcSEcCtD
Tizanidine—Oedema—Mitoxantrone—lymphatic system cancer	0.00109	0.00112	CcSEcCtD
Tizanidine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00109	0.00112	CcSEcCtD
Tizanidine—Nausea—Fludarabine—lymphatic system cancer	0.00109	0.00112	CcSEcCtD
Tizanidine—Infection—Mitoxantrone—lymphatic system cancer	0.00108	0.00112	CcSEcCtD
Tizanidine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00108	0.00111	CcSEcCtD
Tizanidine—Shock—Mitoxantrone—lymphatic system cancer	0.00107	0.0011	CcSEcCtD
Tizanidine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00107	0.0011	CcSEcCtD
Tizanidine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00107	0.0011	CcSEcCtD
Tizanidine—Urticaria—Bleomycin—lymphatic system cancer	0.00107	0.0011	CcSEcCtD
Tizanidine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00106	0.0011	CcSEcCtD
Tizanidine—Body temperature increased—Bleomycin—lymphatic system cancer	0.00106	0.00109	CcSEcCtD
Tizanidine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00106	0.00109	CcSEcCtD
Tizanidine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00105	0.00109	CcSEcCtD
Tizanidine—Paraesthesia—Carmustine—lymphatic system cancer	0.00105	0.00108	CcSEcCtD
Tizanidine—Mood swings—Methotrexate—lymphatic system cancer	0.00105	0.00108	CcSEcCtD
Tizanidine—Hypotension—Vincristine—lymphatic system cancer	0.00105	0.00108	CcSEcCtD
Tizanidine—Dyspnoea—Carmustine—lymphatic system cancer	0.00105	0.00108	CcSEcCtD
Tizanidine—Somnolence—Carmustine—lymphatic system cancer	0.00104	0.00107	CcSEcCtD
Tizanidine—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00102	0.00105	CcSEcCtD
Tizanidine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00102	0.00105	CcSEcCtD
Tizanidine—Hypotension—Mitoxantrone—lymphatic system cancer	0.00102	0.00105	CcSEcCtD
Tizanidine—Paraesthesia—Vincristine—lymphatic system cancer	0.00101	0.00104	CcSEcCtD
Tizanidine—Constipation—Carmustine—lymphatic system cancer	0.001	0.00103	CcSEcCtD
Tizanidine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000994	0.00102	CcSEcCtD
Tizanidine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000991	0.00102	CcSEcCtD
Tizanidine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00098	0.00101	CcSEcCtD
Tizanidine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000973	0.001	CcSEcCtD
Tizanidine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00097	0.000998	CcSEcCtD
Tizanidine—Feeling abnormal—Carmustine—lymphatic system cancer	0.000967	0.000995	CcSEcCtD
Tizanidine—Fatigue—Vincristine—lymphatic system cancer	0.000966	0.000994	CcSEcCtD
Tizanidine—Asthenia—Bleomycin—lymphatic system cancer	0.000965	0.000993	CcSEcCtD
Tizanidine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00096	0.000989	CcSEcCtD
Tizanidine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00096	0.000988	CcSEcCtD
Tizanidine—Constipation—Vincristine—lymphatic system cancer	0.000958	0.000986	CcSEcCtD
Tizanidine—Asthma—Methotrexate—lymphatic system cancer	0.000956	0.000984	CcSEcCtD
Tizanidine—Pruritus—Bleomycin—lymphatic system cancer	0.000951	0.000979	CcSEcCtD
Tizanidine—Fatigue—Mitoxantrone—lymphatic system cancer	0.000941	0.000968	CcSEcCtD
Tizanidine—Constipation—Mitoxantrone—lymphatic system cancer	0.000933	0.00096	CcSEcCtD
Tizanidine—Abdominal pain—Carmustine—lymphatic system cancer	0.000928	0.000955	CcSEcCtD
Tizanidine—Body temperature increased—Carmustine—lymphatic system cancer	0.000928	0.000955	CcSEcCtD
Tizanidine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000916	0.000943	CcSEcCtD
Tizanidine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000899	0.000925	CcSEcCtD
Tizanidine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000892	0.000918	CcSEcCtD
Tizanidine—Abdominal pain—Vincristine—lymphatic system cancer	0.000886	0.000912	CcSEcCtD
Tizanidine—Body temperature increased—Vincristine—lymphatic system cancer	0.000886	0.000912	CcSEcCtD
Tizanidine—Urticaria—Mitoxantrone—lymphatic system cancer	0.000867	0.000892	CcSEcCtD
Tizanidine—Hypersensitivity—Carmustine—lymphatic system cancer	0.000865	0.00089	CcSEcCtD
Tizanidine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000863	0.000888	CcSEcCtD
Tizanidine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000863	0.000888	CcSEcCtD
Tizanidine—Pneumonia—Methotrexate—lymphatic system cancer	0.000857	0.000882	CcSEcCtD
Tizanidine—Vomiting—Bleomycin—lymphatic system cancer	0.000855	0.00088	CcSEcCtD
Tizanidine—Drowsiness—Methotrexate—lymphatic system cancer	0.000852	0.000877	CcSEcCtD
Tizanidine—Depression—Methotrexate—lymphatic system cancer	0.00085	0.000875	CcSEcCtD
Tizanidine—Rash—Bleomycin—lymphatic system cancer	0.000848	0.000873	CcSEcCtD
Tizanidine—Dermatitis—Bleomycin—lymphatic system cancer	0.000847	0.000872	CcSEcCtD
Tizanidine—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000845	0.00087	CcSEcCtD
Tizanidine—Asthenia—Carmustine—lymphatic system cancer	0.000842	0.000867	CcSEcCtD
Tizanidine—Renal failure—Methotrexate—lymphatic system cancer	0.000838	0.000862	CcSEcCtD
Tizanidine—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000829	0.000853	CcSEcCtD
Tizanidine—Hypersensitivity—Vincristine—lymphatic system cancer	0.000825	0.00085	CcSEcCtD
Tizanidine—Sweating—Methotrexate—lymphatic system cancer	0.000817	0.000841	CcSEcCtD
Tizanidine—Haematuria—Methotrexate—lymphatic system cancer	0.000813	0.000837	CcSEcCtD
Tizanidine—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000806	0.00083	CcSEcCtD
Tizanidine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000804	0.000827	CcSEcCtD
Tizanidine—Asthenia—Vincristine—lymphatic system cancer	0.000804	0.000827	CcSEcCtD
Tizanidine—Diarrhoea—Carmustine—lymphatic system cancer	0.000803	0.000827	CcSEcCtD
Tizanidine—Nausea—Bleomycin—lymphatic system cancer	0.000799	0.000822	CcSEcCtD
Tizanidine—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000795	0.000819	CcSEcCtD
Tizanidine—Asthenia—Mitoxantrone—lymphatic system cancer	0.000783	0.000806	CcSEcCtD
Tizanidine—Dizziness—Carmustine—lymphatic system cancer	0.000776	0.000799	CcSEcCtD
Tizanidine—Haemoglobin—Methotrexate—lymphatic system cancer	0.000769	0.000792	CcSEcCtD
Tizanidine—Diarrhoea—Vincristine—lymphatic system cancer	0.000767	0.000789	CcSEcCtD
Tizanidine—Hepatitis—Methotrexate—lymphatic system cancer	0.000765	0.000788	CcSEcCtD
Tizanidine—Haemorrhage—Methotrexate—lymphatic system cancer	0.000765	0.000788	CcSEcCtD
Tizanidine—Pharyngitis—Methotrexate—lymphatic system cancer	0.000759	0.000782	CcSEcCtD
Tizanidine—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000756	0.000778	CcSEcCtD
Tizanidine—Urethral disorder—Methotrexate—lymphatic system cancer	0.00075	0.000772	CcSEcCtD
Tizanidine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000747	0.000768	CcSEcCtD
Tizanidine—Vomiting—Carmustine—lymphatic system cancer	0.000746	0.000768	CcSEcCtD
Tizanidine—Dizziness—Vincristine—lymphatic system cancer	0.000741	0.000763	CcSEcCtD
Tizanidine—Rash—Carmustine—lymphatic system cancer	0.00074	0.000762	CcSEcCtD
Tizanidine—Dermatitis—Carmustine—lymphatic system cancer	0.000739	0.000761	CcSEcCtD
Tizanidine—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000723	0.000745	CcSEcCtD
Tizanidine—Tinnitus—Methotrexate—lymphatic system cancer	0.000713	0.000734	CcSEcCtD
Tizanidine—Vomiting—Vincristine—lymphatic system cancer	0.000712	0.000733	CcSEcCtD
Tizanidine—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00071	0.000731	CcSEcCtD
Tizanidine—Rash—Vincristine—lymphatic system cancer	0.000706	0.000727	CcSEcCtD
Tizanidine—Dermatitis—Vincristine—lymphatic system cancer	0.000706	0.000726	CcSEcCtD
Tizanidine—Nausea—Carmustine—lymphatic system cancer	0.000697	0.000718	CcSEcCtD
Tizanidine—Angiopathy—Methotrexate—lymphatic system cancer	0.000694	0.000715	CcSEcCtD
Tizanidine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000694	0.000714	CcSEcCtD
Tizanidine—Immune system disorder—Methotrexate—lymphatic system cancer	0.000691	0.000711	CcSEcCtD
Tizanidine—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00069	0.00071	CcSEcCtD
Tizanidine—Rash—Mitoxantrone—lymphatic system cancer	0.000688	0.000708	CcSEcCtD
Tizanidine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000687	0.000707	CcSEcCtD
Tizanidine—Alopecia—Methotrexate—lymphatic system cancer	0.000676	0.000696	CcSEcCtD
Tizanidine—Mental disorder—Methotrexate—lymphatic system cancer	0.00067	0.00069	CcSEcCtD
Tizanidine—Nausea—Vincristine—lymphatic system cancer	0.000666	0.000685	CcSEcCtD
Tizanidine—Nausea—Mitoxantrone—lymphatic system cancer	0.000648	0.000667	CcSEcCtD
Tizanidine—Back pain—Methotrexate—lymphatic system cancer	0.000644	0.000663	CcSEcCtD
Tizanidine—Vision blurred—Methotrexate—lymphatic system cancer	0.000628	0.000646	CcSEcCtD
Tizanidine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000618	0.000636	CcSEcCtD
Tizanidine—Anaemia—Methotrexate—lymphatic system cancer	0.000616	0.000634	CcSEcCtD
Tizanidine—Malaise—Methotrexate—lymphatic system cancer	0.000601	0.000618	CcSEcCtD
Tizanidine—Vertigo—Methotrexate—lymphatic system cancer	0.000598	0.000616	CcSEcCtD
Tizanidine—Leukopenia—Methotrexate—lymphatic system cancer	0.000596	0.000614	CcSEcCtD
Tizanidine—Convulsion—Methotrexate—lymphatic system cancer	0.000577	0.000594	CcSEcCtD
Tizanidine—Arthralgia—Methotrexate—lymphatic system cancer	0.000567	0.000584	CcSEcCtD
Tizanidine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000563	0.00058	CcSEcCtD
Tizanidine—Discomfort—Methotrexate—lymphatic system cancer	0.00056	0.000577	CcSEcCtD
Tizanidine—Confusional state—Methotrexate—lymphatic system cancer	0.000548	0.000564	CcSEcCtD
Tizanidine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000544	0.00056	CcSEcCtD
Tizanidine—Infection—Methotrexate—lymphatic system cancer	0.00054	0.000556	CcSEcCtD
Tizanidine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000533	0.000549	CcSEcCtD
Tizanidine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000532	0.000548	CcSEcCtD
Tizanidine—Skin disorder—Methotrexate—lymphatic system cancer	0.000528	0.000544	CcSEcCtD
Tizanidine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000526	0.000541	CcSEcCtD
Tizanidine—Hypotension—Methotrexate—lymphatic system cancer	0.000508	0.000523	CcSEcCtD
Tizanidine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000495	0.00051	CcSEcCtD
Tizanidine—Paraesthesia—Methotrexate—lymphatic system cancer	0.000488	0.000502	CcSEcCtD
Tizanidine—Dyspnoea—Methotrexate—lymphatic system cancer	0.000485	0.000499	CcSEcCtD
Tizanidine—Somnolence—Methotrexate—lymphatic system cancer	0.000483	0.000497	CcSEcCtD
Tizanidine—Dyspepsia—Methotrexate—lymphatic system cancer	0.000479	0.000493	CcSEcCtD
Tizanidine—Fatigue—Methotrexate—lymphatic system cancer	0.000469	0.000482	CcSEcCtD
Tizanidine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000448	0.000461	CcSEcCtD
Tizanidine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000445	0.000458	CcSEcCtD
Tizanidine—Urticaria—Methotrexate—lymphatic system cancer	0.000432	0.000445	CcSEcCtD
Tizanidine—Abdominal pain—Methotrexate—lymphatic system cancer	0.00043	0.000442	CcSEcCtD
Tizanidine—Body temperature increased—Methotrexate—lymphatic system cancer	0.00043	0.000442	CcSEcCtD
Tizanidine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000401	0.000412	CcSEcCtD
Tizanidine—Asthenia—Methotrexate—lymphatic system cancer	0.00039	0.000401	CcSEcCtD
Tizanidine—Pruritus—Methotrexate—lymphatic system cancer	0.000385	0.000396	CcSEcCtD
Tizanidine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000372	0.000383	CcSEcCtD
Tizanidine—Dizziness—Methotrexate—lymphatic system cancer	0.000359	0.00037	CcSEcCtD
Tizanidine—Vomiting—Methotrexate—lymphatic system cancer	0.000346	0.000356	CcSEcCtD
Tizanidine—Rash—Methotrexate—lymphatic system cancer	0.000343	0.000353	CcSEcCtD
Tizanidine—Dermatitis—Methotrexate—lymphatic system cancer	0.000342	0.000352	CcSEcCtD
Tizanidine—Nausea—Methotrexate—lymphatic system cancer	0.000323	0.000332	CcSEcCtD
